An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
about
Interferon lambda: a new sword in cancer immunotherapyAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesKASL clinical practice guidelines: management of hepatitis CUpdate on the treatment of patients with non-genotype 1 hepatitis C virus infectionImpact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsConsensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Hepatitis C in Argentina: epidemiology and treatment.The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virusResponse prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionEffectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trialPegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolutionIL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda.Interferon lambdas: the next cytokine stormSteatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3.IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive associationThe Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.Predictive factors associated with hepatitis C antiviral therapy response.Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.
P2860
Q21296797-A7C69C30-F05F-4EA3-8D94-FF7B393F2E3CQ24632766-1A05E7EF-1E23-41C3-B783-04AEAF265060Q26752471-819C9FAD-2952-41C8-AEE5-728AEDD9A608Q27000806-E2AEF8C0-BE07-4B58-ABED-A7D9B5D287B7Q28732828-18EB7EE6-6210-4316-A72A-A75395E9044BQ29417108-D2C15119-106D-4B84-997F-39B07B3FD2FCQ30365599-8DAF794F-3804-4A3A-9D7C-4CD805942625Q30417045-58663355-2788-4064-A3C8-D5C6C1017371Q30453975-4E7C78AF-D2D1-478E-9BC7-71D20E15525AQ33350754-57642708-1556-4B08-8C49-368BF1E875A4Q33408167-41CA292C-43EF-4D08-B6B7-1D21E0562412Q33559298-9662AE0E-74D6-4E40-87BB-5DE8750E9A1EQ33706737-9CBD7B1C-3431-4712-B00F-21242575B255Q33706886-3277FADE-D7BB-458A-A311-6E6E771CF3D2Q33755525-0AEC0BA3-9256-4269-A84E-64557F9E6640Q33807010-BE24D085-E721-4E81-BF95-CA601AF988ACQ33842239-7CC3412F-56EF-4126-A6FA-26DD9FD21071Q33867243-E39DDEAC-F740-4FC2-BAD2-C3EF563FC9FCQ33938574-54AEECB6-3D25-4DA3-AC22-74A8D330F8B6Q33945882-85F9A3E9-435A-42B8-A233-EB6057588DE6Q34007851-65A32313-6582-4D84-9CEB-815CFF80859BQ34375569-81226DC7-8D31-41C5-B136-B92AE08B9E1DQ34395502-FB6DA965-5753-4852-9E98-38A4B3FE9B2DQ34429833-D78A9B37-E568-4BF7-BC68-2E91CEE7627FQ34464613-E7BD171D-764F-462C-9E2C-0B8D7E1E150DQ34485088-FC76AC97-C7EE-43CE-8AA0-1DF4A57B1FEEQ34626479-F23107FE-706F-4479-AE86-AACD92825E95Q34634369-71EAD3AC-00E2-43C3-9580-7CFC2EB2222EQ35077995-6F848FB3-248F-4A35-B121-5F9CF1FDB262Q35121645-6FA33FC4-BF09-4E81-B8E3-2020B0DE84E3Q35124008-44015F16-DB5C-427B-897B-35FDE8C09DF0Q35137523-708DEBD0-FF3A-4584-9DAA-20D12A8B633CQ35154826-69D4C3D7-40AD-4D87-A7DB-23FDD404AFF1Q35164100-17F4EC72-4D8A-4C48-AC18-2596B0988037Q35270237-09EF17D5-7309-49E6-9B6C-E6003D40384DQ35308700-C2488C1A-53D0-4207-B71C-FB2C68C1AAEDQ35532835-C77C2736-9665-494E-8D9D-7B9270EC7D4EQ35764210-DFC997E6-3C2C-497A-9EB6-C771F3C73649Q35790397-78AF15D2-7A02-4AA8-A0EA-8C5AFFBFC71BQ35803105-9AC5600F-1E12-4745-81FF-28922BE4B1C8
P2860
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
An IL28B polymorphism determin ...... ve a rapid virologic response.
@en
An IL28B polymorphism determin ...... ve a rapid virologic response.
@nl
type
label
An IL28B polymorphism determin ...... ve a rapid virologic response.
@en
An IL28B polymorphism determin ...... ve a rapid virologic response.
@nl
prefLabel
An IL28B polymorphism determin ...... ve a rapid virologic response.
@en
An IL28B polymorphism determin ...... ve a rapid virologic response.
@nl
P2093
P50
P1433
P1476
An IL28B polymorphism determin ...... ve a rapid virologic response.
@en
P2093
Alessandra Mangia
Alexander J Thompson
Daniela Petruzzellis
David B Goldstein
Donato Bacca
Hans L Tillmann
John G McHutchison
Kevin V Shianna
Keyur Patel
Nicola Minerva
P304
821-7, 827.e1
P356
10.1053/J.GASTRO.2010.05.079
P407
P577
2010-06-02T00:00:00Z